MedTrace Logo

Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

NCT03426254 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2023-03-29

No results posted yet for this study

Summary

To assess the safety and efficacy of two forms of Talazoparib therapy (injections subcutaneously Talazoparib and oral form for the treatment in the equivalent therapeutics dose

Conditions

  • Advanced or Recurrent Solid Tumors
  • Breast Neoplasm

Interventions

BIOLOGICAL

Injections Subcutaneously Talazoparib

Patients receive per day single dose of subcutaneous Injection contains 1 mg Talazoparib on days 1-28

DRUG

Oral capsules Talazoparib

Patients receive 1 mg of Talazoparib PO QD on days 1-28.

Sponsors & Collaborators

  • BioGene Pharmaceutical

    collaborator UNKNOWN

  • Center Trials & Treatment

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-10
Primary Completion
2023-12-10
Completion
2024-01-10

Countries

  • Albania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03426254 on ClinicalTrials.gov